Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Impact of genetic alterations on mTOR-targeted cancer therapy.

Chinese journal of cancer - 1 May 2013

Sun Shi-Yong

Abstract excerpt

Rapamycin and its derivatives (rapalogs), a group of allosteric inhibitors of mammalian target of rapamycin (mTOR), have been actively tested in a variety of cancer clinical trials, and some have been approved by the Food and Drug Administration for the treatment of certain types of cancers. However, the single agent activity of these compounds in many tumor types remains modest. The mTOR axis is regulated by...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to AMP-Activated Protein Kinase Kinases
Share to Antibiotics, Antineoplastic
Share to Class I Phosphatidylinositol 3-Kinases

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Phosphatidylinositol 3-Kinases

Share to PTEN Phosphohydrolase

Share to ras Proteins

Share to Sirolimus

Share to TOR Serine-Threonine Kinases

Source

Open in PubMed Open full text

Identifiers

PMID: 23489586
DOI: 10.5732/cjc.013.10005
PMCID: PMC3845552

Genes

KRAS
PTEN

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Impact of genetic alterations on mTOR-targeted cancer therapy.PMID 23489586Read ↗

A diverse array of cancer-associated MTOR mutations are hyperactivating and can predict rapamycin sensitivity.Semantic proximity Read ↗

Drug discovery targeting the mTOR pathwaySemantic proximity Read ↗

An expanding role for mTOR in cancer.Semantic proximity Read ↗

Mutations and deregulation of Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascades which alter therapy response.Semantic proximity Read ↗

Overcoming mTOR resistance mutations with a new-generation mTOR inhibitor.Semantic proximity Read ↗

PI3K/Akt/mTOR Pathway and Its Role in Cancer Therapeutics: Are We Making Headway?Semantic proximity Read ↗

PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancerSemantic proximity Read ↗

Role of the Mammalian Target of Rapamycin Pathway in Liver Cancer: From Molecular Genetics to Targeted TherapiesSemantic proximity Read ↗

Mechanisms of resistance to rapamycins.Semantic proximity Read ↗

Targeting the PI3K/AKT/mTOR and RAF/MEK/ERK pathways for cancer therapySemantic proximity Read ↗

Targeting the mammalian target of rapamycin (mTOR): a new approach to treating cancerSemantic proximity Read ↗

Enhancing mTOR-targeted cancer therapySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.